Molecular mechanisms of anti-cancer activities of β-elemene: Targeting hallmarks of cancer

Mini-Reviews in Medicinal Chemistry

Volumn 16, Issue 17, 2016, Pages 1426-1434

  Jiang, Shiyu ^a   Ling, Chunhua ^b   Li, Wei ^b   Jiang, Hongxin ^c   Zhi, Qiaoming ^b   Jiang, Min ^b  

^a CANCER HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c SUZHOU MUNICIPAL HOSPITAL   (China)

Author keywords

Anti cancer activity; Drug resistance; Hallmarks of cancer; elemene

Indexed keywords

BETA ELEMENE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; BETA-ELEMENE; SESQUITERPENE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE ARREST; CELL DEATH; CHINESE MEDICINE; CURCUMA ZEDOARIA; CYTOTOXICITY; DNA DAMAGE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; MULTIDRUG RESISTANCE; NEOPLASM; PROTEIN EXPRESSION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UPREGULATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ISOLATION AND PURIFICATION; METABOLISM; NEOPLASMS; PATHOLOGY; RHIZOME; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; RHIZOME; SESQUITERPENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84992381823     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1871520616666160211123424     Document Type: Article

References (102)

1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2015. CA. Cancer J. Clin., 2015, 65, 5-29.
2. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA. Cancer J. Clin., 2011, 61, 69-90.
3. DeSantis, C.E.; Lin, C.C.; Mariotto, A.B.; Siegel, R.L.; Stein, K.D.; Kramer, J.L.; Alteri, R.; Robbins, A.S.; Jemal, A. Cancer treatment and survivorship statistics, 2014. CA. Cancer J. Clin., 2014, 64, 252-271.
4. Holohan, C.; Van Schaeybroeck, S.; Longley, D.B.; Johnston, P.G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer, 2013, 13, 714-726.
5. Shen, H.; Laird, P.W. Interplay between the cancer genome and epigenome. Cell, 2013, 153, 38-55.
6. Burrell, R.A.; McGranahan, N.; Bartek, J.; Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature, 2013, 501, 338-345.
7. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell, 2011, 144, 646-674.
8. Hainaut, P.; Plymoth, A. Targeting the hallmarks of cancer: Towards a rational approach to next-generation cancer therapy. Curr. Opin. Oncol., 2013, 25, 50-51.
9. Jiang M.; Huang, O.; Zhang, X.; Xie, Z.; Shen, A.; Liu, H.; Geng, M.; Shen, K. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules, 2013, 18, 701-720.
10. Huang, O.; Xie, Z.; Zhang, W.; Lou, Y.; Mao, Y.; Liu, H.; Jiang, M.; Shen, K. A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrineresistant breast cancer cells. Oncol. Rep., 2014, 32, 627-634.
11. Limaverde-Sousa, G.; Sternberg, C.; Ferreira, C.G. Antiangiogenesis beyond VEGF inhibition: A journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat. Rev., 2014, 40, 548-557.
12. Goss, P.E.; Strasser-Weippl, K.; Lee-Bychkovsky, B.L.; Fan, L.; Li, J.; Chavarri-Guerra, Y.; Liedke, P.E.; Pramesh, C.S.; Badovinac-Crnjevic, T.; Sheikine, Y.; Chen, Z.; Qiao, Y.L.; Shao, Z.; Wu, Y.L.; Fan, D.; Chow, L.W.; Wang, J.; Zhang, Q.; Yu, S.; Shen, G.; He, J.; Purushotham, A.; Sullivan, R.; Badwe, R.; Banavali, S.D.; Nair, R.; Kumar, L.; Parikh, P.; Subramanian, S.; Chaturvedi, P.; Iyer, S.; Shastri, S.S.; Digumarti, R.; Soto-Perez-de-Celis, E.; Adilbay, D.; Semiglazov, V.; Orlov, S.; Kaidarova, D.; Tsimafeyeu, I.; Tatishchev, S.; Danishevskiy, K.D.; Hurlbert, M.; Vail, C.; St Louis, J.; Chan, A. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol., 2014, 15, 489-538.
13. Hanahan, D. Rethinking the war on cancer. Lancet, 2014, 383, 558-563.
14. Li, X.; Yang, G.; Zhang, Y.; Yang, J.; Chang, J.; Sun, X.; Zhou, X.; Guo, Y.; Xu, Y.; Liu, J.; Bensoussan, A. Traditional Chinese medicine in cancer care: A review of controlled clinical studies published in chinese. PLoSOne, 2013, 8, e60338.
15. Aggarwal, B.B.; Yuan, W.; Li, S.; Gupta, S.C. Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric. Mol. Nutr. Food Res., 2013, 57, 1529-1542.
16. Wu, X.S.; Xie, T.; Lin, J.; Fan, H.Z.; Huang-Fu, H.J.; Ni, L.F.; Yan, H.F. An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas. J. Pharm. Pharmacol., 2009, 61, 1653-1656.
17. Xu, H.B.; Zheng, L.P.; Li, L.; Xu, L.Z.; Fu, J. Elemene, one ingredient of a Chinese herb, against malignant tumors: A literature-based meta-analysis. Cancer Invest., 2013, 31, 156-166.
18. Lee, R.X.; Li, Q.Q.; Reed, E. beta-elemene effectively suppresses the growth and survival of both platinum-sensitive and-resistant ovarian tumor cells. Anticancer Res., 2012, 32, 3103-3113.
19. Zhu, T.Z.; Li, X.M.; Luo, L.H.; Xu, Y.H.; Cao, P.; Liu, Y.; Liang, G.B. beta-Elemene inhibits proliferation through crosstalk between glia maturation factor beta and extracellular signalregulated kinase 1/2 and impairs drug resistance to temozolomide in glioblastoma cells. Mol. Med. Rep., 2014, 10, 1122-1128.
20. Zou, B.; Li, Q.Q.; Zhao, J.; Li, J.M.; Cuff, C.F.; Reed, E. beta-Elemene and taxanes synergistically induce cytotoxicity and inhibit proliferation in ovarian cancer and other tumor cells. Anticancer Res., 2013, 33, 929-940.
21. Lu, X.; Wang, Y.; Luo, H.; Qiu, W.; Han, H.; Chen, X.; Yang, L. beta-elemene inhibits the proliferation of T24 bladder carcinoma cells through upregulation of the expression of Smad4. Mol. Med. Rep., 2013, 7, 513-518.
22. Yan, B.; Zhou, Y.; Feng, S.; Lv, C.; Xiu, L.; Zhang, Y.; Shi, J.; Li, Y.; Wei, P.; Qin, Z. beta-Elemene-attenuated tumor angiogenesis by targeting notch-1 in gastric cancer stem-like cells. Evid. Based Complement. Alternat. Med., 2013, 2013, 268468.
23. Chen, W.; Lu, Y.; Wu, J.; Gao, M.; Wang, A.; Xu, B. Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis. Cancer Chemother. Pharmacol., 2011, 67, 799-808.
24. Li, L.J.; Zhong, L.F.; Jiang, L.P.; Geng, C.Y.; Zhu, T.Z.; Xu, Y.H.; Wang, Q.; Qu, Y.; Shao, J.; Zou, L.J. Lysosomal membrane permeabilization contributes to elemene emulsion-induced apoptosis in A549 cells. Free Radic. Res., 2011, 45, 1232-1240.
25. Yu, Z.; Wang, R.; Xu, L.; Xie, S.; Dong, J.; Jing, Y. beta-Elemene piperazine derivatives induce apoptosis in human leukemia cells through downregulation of c-FLIP and generation of ROS. PLoSOne, 2011, 6, e15843.
26. Xie, C.Y.; Yang, W.; Li, M.; Ying, J.; Tao, S.J.; Li, K.; Dong, J.H.; Wang, X.S. Cell apoptosis induced by delta-elemene in colorectal adenocarcinoma cells via a mitochondrial-mediated pathway. Yakugaku Zasshi., 2009, 129, 1403-1413.
27. Liu, J.; Hu, X.J.; Jin, B.; Qu, X.J.; Hou, K.Z.; Liu, Y.P. beta-Elemene induces apoptosis as well as protective autophagy in human non-small-cell lung cancer A549 cells. J. Pharm. Pharmacol., 2012, 64, 146-153.
28. Liu, J.; Zhang, Y.; Qu, J.; Xu, L.; Hou, K.; Zhang, J.; Qu, X.; Liu, Y. Beta-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer, 2011, 11, 183.
29. Zhang, X.; Zhang, Y.; Li, Y. Beta-elemene decreases cell invasion by upregulating E-cadherin expression in MCF-7 human breast cancer cells. Oncol. Rep., 2013, 30, 745-750.
30. Zhang, X.; Li, Y.; Zhang, Y.; Song, J.; Wang, Q.; Zheng, L.; Liu, D. Beta-elemene blocks epithelial-mesenchymal transition in human breast cancer cell line MCF-7 through Smad3-mediated down-regulation of nuclear transcription factors. PLoSOne, 2013, 8, e58719.
31. Shi, H.; Liu, L.; Geng, J.; Zhou, Y.; Chen, L. Beta-Elemene inhibits the metastasis of B16F10 melanoma cells by downregulation of the expression of uPA, uPAR, MMP-2, and MMP-9. Melanoma. Res., 2014, 24, 99-107.
32. Gutschner, T.; Diederichs, S. The hallmarks of cancer: A long noncoding RNA point of view. RNA Biol., 2012, 9, 703-719.
33. Dhillon, A.S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer. Oncogene, 2007, 26, 3279-3290.
34. Boutros, T.; Chevet, E.; Metrakos, P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: Roles in cell growth, death and cancer. Pharmacol. Rev., 2008, 60, 261-310.
35. Yao, Y.Q.; Ding, X.; Jia, Y.C.; Huang, C.X.; Wang, Y.Z.; Xu, Y.H. Anti-tumor effect of beta-elemene in glioblastoma cells depends on p38 MAPK activation. Cancer Lett., 2008, 264, 127-134.
36. Zhao, Y.S.; Zhu, T.Z.; Chen, Y.W.; Yao, Y.Q.; Wu, C.M.; Wei, Z.Q.; Wang, W.; Xu, Y.H. Beta-elemene inhibits Hsp90/Raf-1 molecular complex inducing apoptosis of glioblastoma cells. J. Neurooncol., 2012, 107, 307-314.
37. Li, L.; Xu, L.; Qu, X.; Zhao, M; Yu, P.; Kang, J.; Liu, Y.; Hu, X. Cbl-regulated Akt and ERK signals are involved in beta-elemeneinduced cell apoptosis in lung cancer cells. Mol. Med. Rep., 2011, 4, 1243-1246.
38. Zhao, S.; Wu, J.; Zheng, F.; Tang, Q.; Yang, L.; Li, L.; Wu, W.; Hann, S.S. beta-elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPKalpha signalling pathways in human lung cancer cells: The role of Sp1. J. Cell Mol. Med., 2015, 19, 630-641.
39. Zhan, Y.H.; Liu, J.; Qu, X.J.; Hou, K.Z.; Wang, K.F.; Liu, Y.P.; Wu, B. Beta-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK/ERK and PI3K/Akt/ mTOR signalling pathways. Asi. Pac. J. Cancer Prev., 2012, 13, 2739-2744.
40. Li, Q.Q.; Lee, R.X.; Liang, H.; Wang, G.; Li, J.M.; Zhong, Y.; Reed, E. Beta-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int. J. Oncol., 2013, 43, 721-728.
41. Zhang, Y.; Mu, X.D.; Li, E.Z.; Luo, Y.; Song, N.; Qu, X.J.; Hu, X.J.; Liu, Y.P. The role of E3 ubiquitin ligase cbl proteins in betaelemene reversing multi-drug resistance of human gastric adenocarcinoma cells. Int. J. Mol. Sci., 2013, 14, 10075-10089.
42. Zou, K.; Tong, E.; Xu, Y.; Deng, X.; Zou, L. Down regulation of mammalian target of rapamycin decreases HIF-1alpha and survivin expression in anoxic lung adenocarcinoma A549 cell to elemene and/or irradiation. Tumour Biol., 2014, 35, 9735-9741.
43. Liang, D.; Yang, M.; Guo, B.; Yang, L.; Cao, J.; Zhang, X. HIF-1alpha induced by beta-elemene protects human osteosarcoma cells from undergoing apoptosis. J. Cancer Res. Clin. Oncol., 2012, 138, 1865-1877.
44. Tong, E.; Xu, Y.; Li, G.; Zou, K.; Zou, L. The effects of betaelemene on the expression of mTOR, HIF-1A, survivin in lung adenocarcinoma A549 cell. Afr. J. Tradit. Complement. Altern. Med., 2013, 10, 18-23.
45. Ma, L.; Chen, Z.; Erdjument-Bromage, H.; Tempst, P.; Pandolfi, P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell, 2005, 121, 179-193.
46. Carracedo, A.; Ma, L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A.T.; Thomas, G.; Kozma, S.C.; Papa, A.; Nardella, C.; Cantley, L.C.; Baselga, J.; Pandolfi, P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest., 2008, 118, 3065-3074.
47. Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer, 2009, 9, 153-166.
48. Bruyere, C.; Meijer, L. Targeting cyclin-dependent kinases in antineoplastic therapy. Curr. Opin. Cell Biol., 2013, 25, 772-779.
49. Wang, G.; Li, X.; Huang, F.; Zhao, J.; Ding, H.; Cunningham, C.; Coad, J.E.; Flynn, D.C.; Reed, E.; Li, Q.Q. Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell. Mol. Life Sci., 2005, 62, 881-893.
50. Li, Q.Q.; Wang, G.; Huang, F.; Li, J.M.; Cuff, C.F.; Reed, E. Sensitization of lung cancer cells to cisplatin by beta-elemene is mediated through blockade of cell cycle progression: Antitumor efficacies of beta-elemene and its synthetic analogs. Med. Oncol., 2013, 30, 488.
51. Li, X.; Wang, G.; Zhao, J.; Ding, H.; Cunningham, C.; Chen, F.; Flynn, D.C.; Reed, E.; Li, Q.Q. Antiproliferative effect of betaelemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol. Life Sci., 2005, 62, 894-904.
52. Dai, Z.J.; Tang, W.; Lu, W.F.; Gao, J.; Kang, H.F.; Ma, X.B.; Min, W.L.; Wang, X.J.; Wu, W.Y. Antiproliferative and apoptotic effects of beta-elemene on human hepatoma HepG2 cells. Cancer Cell Int., 2013, 13, 27.
53. Mao, Y.; Zhang, J.; Hou, L.; Cui, X. The effect of beta-elemene on alpha-tubulin polymerization in human hepatoma HepG2 cells. Chin. J. Cancer Res., 2013, 25, 770-776.
54. Zhu, T.; Zhao, Y.; Zhang, J.; Li, L.; Zou, L.; Yao, Y.; Xu, Y. ss-Elemene inhibits proliferation of human glioblastoma cells and causes cell-cycle G0/G1 arrest via mutually compensatory activation of MKK3 and MKK6. Int. J. Oncol., 2011, 38, 419-426.
55. Li, C.L.; Chang, L.; Guo, L.; Zhao, D.; Liu, H.B.; Wang, Q.S.; Zhang, P.; Du, W.Z.; Liu, X.; Zhang, H.T.; Liu, Y.; Zhang, Y.; Xie, J.H.; Ming, J.G.; Cui, Y.Q.; Sun, Y.; Zhang, Z.R.; Jiang, C.L. betaelemene induces caspase-dependent apoptosis in human glioma cells in vitro through the upregulation of Bax and Fas/ FasL and downregulation of Bcl-2. Asi. Pac. J. Cancer Prev., 2014, 15, 10407-10412.
56. Zhu, T.; Xu, Y.; Dong, B.; Zhang, J.; Wei, Z.; Yao, Y. Betaelemene inhibits proliferation of human glioblastoma cells through the activation of glia maturation factor beta and induces sensitization to cisplatin. Oncol. Rep., 2011, 26, 405-413.
57. Zhao, Y.F.; Wang, C.R.; Wu, Y.M.; Ma, S.L.; Ji, Y.; Lu, Y.J. P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment. Biomed. Pharmacother., 2011, 65, 151-156.
58. Jiang, M.; Huang, O.; Xie, Z.; Wu, S.; Zhang, X.; Shen, A.; Liu, H.; Chen, X.; Wu, J.; Lou, Y.; Mao, Y.; Sun, K.; Hu, S.; Geng, M.; Shen, K. A novel long non-coding RNA-ARA: Adriamycin resistance-associated. Biochem. Pharmacol., 2014, 87, 254-283.
59. Leanza, L.; Zoratti, M.; Gulbins, E.; Szabo, I. Mitochondrial ion channels as oncological targets. Oncogene, 2014, 33, 5569-5581.
60. Zhao, J.; Li, Q.Q.; Zou, B.; Wang, G.; Li, X.; Kim, J.E.; Cuff, C.F.; Huang, L.; Reed, E.; Gardner, K. In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma. Int. J. Oncol., 2007, 31, 241-252.
61. Zhang, H.; Xu, F.; Xie, T.; Jin, H.; Shi, L. Beta-elemene induces glioma cell apoptosis by downregulating survivin and its interaction with hepatitis B X-interacting protein. Oncol. Rep., 2012, 28, 2083-2090.
62. Li, Q.Q.; Wang, G.; Huang, F.; Banda, M.; Reed, E. Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J. Pharm. Pharmacol., 2010, 62, 1018-1027.
63. Yu, Z.; Wang, R.; Xu, L.; Dong, J.; Jing, Y. N-(beta-Elemene-13-yl)tryptophan methyl ester induces apoptosis in human leukemia cells and synergizes with arsenic trioxide through a hydrogen peroxide dependent pathway. Cancer Lett., 2008, 269, 165-173.
64. Janku, F.; McConkey, D.J.; Hong, D.S.; Kurzrock, R. Autophagy as a target for anticancer therapy. Nat. Rev. Clin. Oncol., 2011, 8, 528-539.
65. Jain, K.; Paranandi, K.S.; Sridharan, S.; Basu, A. Autophagy in breast cancer and its implications for therapy. Am. J. Cancer. Res., 2013, 3, 251-265.
66. Ding, X.F.; Shen, M.; Xu, L.Y.; Dong, J.H.; Chen, G. 13,14-bis(cis-3,5-dimethyl-1-piperazinyl)-beta-elemene, a novel betaelemene derivative, shows potent antitumor activities via inhibition of mTOR in human breast cancer cells. Oncol. Lett., 2013, 5, 1554-1558.
67. Guan, C.; Liu, W.; Yue, Y.; Jin, H.; Wang, X.; Wang, X.J. Inhibitory effect of beta-elemene on human breast cancer cells. Int. J. Clin. Exp. Pathol., 2014, 7, 3948-3956.
68. Lin, Y.; Wang, K.; Hu, C.; Lin, L.; Qin, S.; Cai, X. Elemene injection induced autophagy protects human hepatoma cancer cells from starvation and undergoing apoptosis. Evid. Based Complement. Alternat. Med., 2014, 2014, 637528.
69. Bieging, K.T.; Mello, S.S.; Attardi, L.D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer, 2014, 14, 359-370.
70. Zhang, F.; Xu, L.; Qu, X.; Zhao, M.; Jin, B.; Kang, J.; Liu, Y.; Hu, X. Synergistic antitumor effect of beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells. Mol. Med. Rep., 2011, 4, 1189-1193.
71. Valente, L.J.; Gray, D.H.; Michalak, E.M.; Pinon-Hofbauer, J.; Egle, A.; Scott, C.L.; Janic, A.; Strasser, A. p53 efficiently suppresses tumor development in the complete absence of its cellcycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep., 2013, 3, 1339-1345.
72. Bieging, K.T.; Attardi, L.D. Deconstructing p53 transcriptional networks in tumor suppression. Trends Cell Biol., 2012, 22, 97-106.
73. Li, J.; Jun, Yu.; Liu, A.; Wang, Y. beta-Elemene against human lung cancer via up-regulation of P53 protein expression to promote the release of exosome. Lung Cancer, 2014, 86, 144-150.
74. Kenzelmann Broz, D.; Spano Mello, S.; Bieging, K.T.; Jiang, D.; Dusek, R.L.; Brady, C.A.; Sidow, A.; Attardi, L.D. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev., 2013, 27, 1016-1031.
75. Wang, Z.; Fukuda, S.; Pelus, L.M. Survivin regulates the p53 tumor suppressor gene family. Oncogene, 2004, 23, 8146-8153.
76. Chen, X.; Wang, Y.; Luo, H.; Luo, Z.; Zhang, T.; Yang, N.; Long, X.; Xie, H.; Qiu, W.; Zhang, B.; Ding, J.; Yang, L. Beta-elemene acts as an antitumor factor and downregulates the expression of survivin, Bcl-xL and Mta-1. Mol. Med. Rep., 2012, 6, 989-995.
77. Li, G.; Xie, B.; Li, X.; Chen, Y.; Wang, Q.; Xu, Y.; Xu-Welliver, M.; Zou, L. Down-regulation of survivin and hypoxia-inducible factor-1 alpha by beta-elemene enhances the radiosensitivity of lung adenocarcinoma xenograft. Cancer Biother. Radiopharm., 2012, 27, 56-64.
78. Harshman, S.W.; Young, N.L.; Parthun, M.R.; Freitas, M.A. H1 histones: Current perspectives and challenges. Nucleic Acids Res., 2013, 41, 9593-9609.
79. Bao, F.; Qiu, J.; Zhang, H. Potential role of beta-elemene on histone H1 in the H22 ascites hepatoma cell line. Mol. Med. Rep., 2012, 6, 185-190.
80. Davis, F.M.; Stewart, T.A.; Thompson, E.W.; Monteith, G.R. Targeting EMT in cancer: Opportunities for pharmacological intervention. Trends Pharmacol. Sci., 2014.
81. Talmadge, J.E.; Fidler, I.J. AACR centennial series: The biology of cancer metastasis: historical perspective. Cancer Res., 2010, 70, 5649-5669.
82. Farnsworth, R.H.; Lackmann, M.; Achen, M.G.; Stacker, S.A. Vascular remodeling in cancer. Oncogene, 2014, 33, 3496-3505.
83. Vasudev, N.S.; Reynolds, A.R. Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions. Angiogenesis, 2014, 17, 471-494.
84. Tao, L.; Zhou, L.; Zheng, L.; Yao, M. Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo. Cancer Chemother. Pharmacol., 2006, 58, 24-34.
85. Takebe, N.; Nguyen, D.; Yang, S.X. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol. Ther., 2014, 141, 140-149.
86. Gong, M.; Liu, Y.; Zhang, J.; Gao, Y.J.; Zhai, P.P.; Su, X.; Li, X.; Li, Y.; Hou, L.; Cui, X.N. Beta-elemene inhibits cell proliferation by regulating the expression and activity of topoisomerases I and IIalpha in human hepatocarcinoma HepG-2 Cells. Biomed. Res. Int., 2015, 2015, 153987.
87. Zhu, T.; Li, X.; Luo, L.; Wang, X.; Li, Z.; Xie, P.; Gao, X.; Song, Z.; Su, J.; Liang, G. Reversion of malignant phenotypes of human glioblastoma cells by beta-elemene through beta-catenin-mediated regulation of stemness-, differentiation-and epithelial-tomesenchymal transition-related molecules. J. Transl. Med., 2015, 13, 356.
88. Gillet, J.P.; Gottesman, M.M. Mechanisms of multidrug resistance in cancer. Methods Mol. Biol., 2010, 596, 47-76.
89. Xu, H.B.; Li, L.; Fu, J.; Mao, X.P.; Xu, L.Z. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by beta-elemene. Pharmacology, 2012, 89, 303-312.
90. Guo, H.Q.; Zhang, G.N.; Wang, Y.J.; Zhang, Y.K.; Sodani, K.; Talele, T.T.; Ashby, C.R. Jr.; Chen, Z.S. Beta-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. Oncol. Rep., 2014, 31, 858-866.
91. Galluzzi, L.; Vitale, I.; Michels, J.; Brenner, C.; Szabadkai, G.; Harel-Bellan, A.; Castedo, M.; Kroemer, G. Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis., 2014, 5, e1257.
92. Li, Q.Q.; Lee, R.X.; Liang, H.; Zhong, Y.; Reed, E. Enhancement of cisplatin-induced apoptosis by beta-elemene in resistant human ovarian cancer cells. Med. Oncol., 2013, 30, 424.
93. Yao, C.C.; Tu, Y.R.; Jiang, J.; Ye, S.F.; Du, H.X.; Zhang, Y. Betaelemene reverses the drug resistance of lung cancer A549/DDP cells via the mitochondrial apoptosis pathway. Oncol. Rep., 2014, 31, 2131-2138.
94. Zhang, J.; Zhang, H.; Chen, L.; Sun da, W.; Mao, C.; Chen, W.; Wu, J.Z.; Zhong, S.L.; Zhao, J.H.; Tang, J.H. Beta-elemene reverses chemoresistance of breast cancer via regulating MDRrelated microRNA expression. Cell Physiol. Biochem., 2014, 34, 2027-2037.
95. Dong, Y.; Li, L.; Wang, L.; Zhou, T.; Liu, J.W.; Gao, Y.J. Preliminary study of the effects of beta-elemene on MCF-7/ADM breast cancer stem cells. Genet. Mol. Res., 2015, 14, 2347-2355.
96. Zhu, T.Z.; Li, X.M.; Luo, L.H.; Song, Z.Q.; Gao, X.; Li, Z.Q.; Su, J.Y.; Liang, G.B. Beta-elemene inhibits stemness promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells. Int. J. Oncol., 2014, 45, 699-709.
97. Zhang, B.; Zhang, X.; Tang, B.; Zheng, P.; Zhang, Y. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor alpha (ERalpha) re-expression. Breast Cancer Res. Treat., 2012, 136, 399-406.
98. Li, L.J.; Zhong, L.F.; Jiang, L.P.; Geng, C.Y.; Zou, L.J. Beta-Elemene radiosensitizes lung cancer A549 cells by enhancing DNA damage and inhibiting DNA repair. Phytother. Res., 2011, 25, 1095-1097.
99. Liu, J.S.; Che, X.M.; Chang, S.; Qiu, G.L.; He, S.C.; Fan, L.; Zhao, W.; Zhang, Z.L.; Wang, S.F. Beta-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation. World J. Gastroenterol., 2015, 21, 9945-9956.
100. Liu, J.S.; He, S.C.; Zhang, Z.L.; Chen, R.; Fan, L.; Qiu, G.L.; Chang, S.; Li, L.; Che, X.M. Anticancer effects of beta-elemene in gastric cancer cells and its potential underlying proteins: a proteomic study. Oncol. Rep., 2014, 32, 2635-2647.
101. Hu, Z.; Wu, H.; Li, Y.; Hou, Q.; Wang, Y.; Li, S.; Xia, B.; Wu, S. Beta-Elemene inhibits the proliferation of esophageal squamous cell carcinoma by regulating long noncoding RNA-mediated inhibition of hTERT expression. Anticancer Drugs, 2015, 26, 531-539.
102. Peng, X.; Zhao, Y.; Liang, X.; Wu, L.; Cui, S.; Guo, A.; Wang, W. Assessing the quality of RCTs on the effect of beta-elemene, one ingredient of a Chinese herb, against malignant tumors. Contemp. Clin. Trials, 2006, 27, 70-82.